307 related articles for article (PubMed ID: 31237886)
1. FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma.
Kang SY; Bang JI; Kang KW; Lee HY; Chung JK
PLoS One; 2019; 14(6):e0218416. PubMed ID: 31237886
[TBL] [Abstract][Full Text] [Related]
2. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
[TBL] [Abstract][Full Text] [Related]
3. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
[TBL] [Abstract][Full Text] [Related]
4. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
[TBL] [Abstract][Full Text] [Related]
5. Distant metastatic lesions in patients with differentiated thyroid carcinoma. Clinical implications of radioiodine and FDG uptake.
Hong CM; Ahn BC; Jeong SY; Lee SW; Lee J
Nuklearmedizin; 2013; 52(4):121-9. PubMed ID: 23928981
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.
Manohar PM; Beesley LJ; Bellile EL; Worden FP; Avram AM
Clin Nucl Med; 2018 Sep; 43(9):641-647. PubMed ID: 30015659
[TBL] [Abstract][Full Text] [Related]
7. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
Valerio L; Guidoccio F; Giani C; Tardelli E; Puccini G; Puleo L; Minaldi E; Boni G; Elisei R; Volterrani D
J Clin Endocrinol Metab; 2021 Jul; 106(8):2355-2366. PubMed ID: 33901285
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
Rizzo A; Perotti G; Zagaria L; Lanni V; Racca M; Palestini N; Salvatori M
Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
[TBL] [Abstract][Full Text] [Related]
9. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.
Triviño Ibáñez EM; Muros MA; Torres Vela E; Llamas Elvira JM
Endocrine; 2016 Mar; 51(3):490-8. PubMed ID: 26224589
[TBL] [Abstract][Full Text] [Related]
10. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract][Full Text] [Related]
11. Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC).
Lodi Rizzini E; Repaci A; Tabacchi E; Zanoni L; Vicennati V; Cavicchi O; Pagotto U; Morganti AG; Fanti S; Monari F
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441364
[TBL] [Abstract][Full Text] [Related]
12.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
13. Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy.
Salvatore B; Klain M; Nicolai E; D'Amico D; De Matteis G; Raddi M; Fonti R; Pellegrino T; Storto G; Cuocolo A; Pace L
Medicine (Baltimore); 2017 Oct; 96(42):e8344. PubMed ID: 29049252
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
[TBL] [Abstract][Full Text] [Related]
15. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
16. The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer.
Terroir M; Borget I; Bidault F; Ricard M; Deschamps F; Hartl D; Tselikas L; Dercle L; Lumbroso J; Baudin E; Berdelou A; Deandreis D; Schlumberger M; Leboulleux S
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):638-646. PubMed ID: 27796544
[TBL] [Abstract][Full Text] [Related]
17. Progression free survival related to
Zhu X; Wu S; Yuan X; Wang H; Ma C
Hell J Nucl Med; 2019; 22(2):123-130. PubMed ID: 31273354
[TBL] [Abstract][Full Text] [Related]
18. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
